The New Zealand Meningococcal Vaccine Strategy: A tailor-made vaccine to combat a devastating epidemic

New Zealand Medical Journal

Volumn 117, Issue 1200, 2004, Pages

  Sexton, Kerry ^a   Lennon, Diana ^b   Oster, Philipp ^c   Crengle, Sue ^b   Martin, Diana ^d   Mulholland, Kim ^e   Percival, Teuila ^f   Reid, Stewart ^g   Stewart, Joanna ^b   O'Hallahan, Jane ^a  

^a MINISTRY OF HEALTH   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Clin Research and Medical Affairs   (Italy)

^d INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

^e Centre for Community Child Health   (Australia)

^f South Auckland Health   (New Zealand)

^g Ropata Medical Centre   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; AWARENESS; BACTERIAL STRAIN; BRAZIL; CHILD; CHILE; CLINICAL TRIAL; CUBA; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; GROUPS BY AGE; HEALTH CARE PLANNING; HEALTH PROMOTION; HEALTH SURVEY; HUMAN; INFANT; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEW ZEALAND; NORWAY; POPULATION RESEARCH; POSTMARKETING SURVEILLANCE; PREVENTIVE HEALTH SERVICE; WORKSHOP; WORLD HEALTH ORGANIZATION; IMMUNOLOGY; ISOLATION AND PURIFICATION; RISK FACTOR;

DISEASE OUTBREAKS; HUMANS; IMMUNIZATION PROGRAMS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; NEW ZEALAND; POPULATION SURVEILLANCE; PRODUCT SURVEILLANCE, POSTMARKETING; RISK FACTORS;

EID: 14844330115     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Martin D, McDowell R. The Epidemiology of Meningococcal Disease in New Zealand in 2003. A report prepared for the Ministry of Health by the Institute of Environmental Science and Research Limited (ESR); 2004. Available online. URL: http://www.moh.govt.nz/moh.nsf/0/c088f437895d6dc8cc256ed1000b2539? OpenDocument Accessed August 2004.
2. Wilson N, Baker M, Martin D, et al. Meningococcal disease epidemiology and control in New Zealand. N Z Med J. 1995;108:437-42.
3. Apicella MA. Neisseria meningitidis. In: Mandell GL, Bennett JE, Dolin R, editors. Mandell, Douglas and Bennett's Principles and practice of infectious disease. 4th ed. New York: Churchill Livingstone; 1995. p1896-909.
4. Idänpään-Heikkilä I, Høviby EA, Chattopadhyay P, et al. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol. 1995;43:335-43.
5. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, I: role of humoral antibodies. J Exp Med. 1969;129:1307-26.
6. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus, II: Development of natural immunity. J Exp Med. 1969;129:1327-48.
7. Gotschlich EC, Goldschneider I, Artenstein, MS. Human immunity to the meningococcus, IV: immunogenicity of the group A and group C polysaccharides in human volunteers. J Exp Med. 1969;129:1367-84.
8. Rosenqvist E, Høiby EA, Wedege E, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun. 1995;63:4642-52.
9. Peeters CC, Rümke HC, Sundermann LC, et al. Phase I clinical trial with a hexavalent porA containing meningococcal outer membrane vesicle vaccine. Vaccine. 1996;14:1009-15.
10. Van der Voort ER, Van der Ley P, Van der Biezen J, et al. Specificity of human bactericidal antibodies against porA P1.7,16 induced with a hexavalent meningococcal outer membrane vesicle vaccine. Infect Immun. 1996;64:2745-51.
11. Perkins BA, Jonsdottir K, Briem H, et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis. 1998;177:683-91.
12. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomised controlled trial in Chile. JAMA. 1999;281:1520-7.
13. Jones GR, Christodoulides M, Brooks JI, et al. Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization. J Infect Dis. 1998;178:451-9.
14. Boslego J, Garcia J, Cruz C, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. 1995;13:821-9.
15. Milagres LC, Ramos SR, Saachi CT, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Immun. 1994;62:4419-24.
16. Holst J, Feiring B, Fuglesang JE, et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine. 2003;21:734-737.
17. Bjune G, Høiby EA, Grønnesby JK, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991;338:1093-96.
18. Sierra GV, Campa HC, Varcacel NM, et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Annals. 1991;14:195-207.
19. DeMoraes JC, Perkins BA, Camargo MCC, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992;340:1074-8.
20. Alea GV, Marinez MI, Sotolongo PF, et al. Phenotypes of Neisseria meningitidis strains isolated in Cuba (1982-2001). In: Caugant DA and Wedege E (ed). Abstracts of the 13th International Pathogenic Neisseria Conference, Oslo 2002. Nordberg Aksidenstrykkeri AS, Oslo, p328.
21. Personal communication, Dr I Aaberge, Norwegian Institute of Public Health, Norway, March 2004.
22. Sexton K, Lennon D, Oster P, et al. Proceedings of the Meningococcal Vaccine Strategy World Health Organization Satellite Meeting, 10 March 2004, Auckland, New Zealand. N Z Med J. 2004;117(1200). URL: http://www.nzma.org.nz/journal/117-1200/1026.
23. Dr Luis Herrera, General Director, CIGB, Cuba 'Biotechnological development at the Western Habana Scientific Pole and Center for Genetic Engineering and Biotechnology'. Opening Lecture. Biotechnology Havan 2003. Havana, Cuba, 23-28 Nov 2003.
24. Devoy A, Dyet KH, Martin DR. Relative Stability of PorA During a Meningococcal Disease Epidemic. Infect Immun. 2004; (manuscript in preparation).